AbbVie diversifies oncology portfolio with $10.1 bn ImmunoGen acquisition

The acquisition allows AbbVie to establish its presence in the ovarian cancer market with Immunogen’s Elahere.

Latest news

FDA accepts Merck's Keytruda plus Padcev sBLA to treat urothelial cancer

The company has submitted the sBLA based on data from the Phase III KEYNOTE-A39 trial.

Generation bio cuts 40% of staff in blow for non-viral gene therapy sector

The move is a strategic response amid challenges faced by the non-viral gene therapy sector, with several startups closing this year.

Cybin reports positive results from major depressive disorder trial

In the trial, tested doses of CYB003 demonstrated to have a favourable safety and tolerability profile.

AML cell therapy trials to watch in 2024 targeting GvHD

Following the approval of NiCord earlier this year, there are more candidates coming to late-stage trials looking to target GvHD.

Pharma's engagement with healthcare providers has slipped in recent years

Changing trends show a reduction in HCP contact with the pharma industry and an increased prioritisation of in-person contact.

CTO Europe 2023: Fostering diverse oncology trials remains a challenge

Experts at the clinical conference continued to explore ways to improve representation in clinical trials and the regulatory push behind it.

BioVie reports protocol deviations in Phase III Alzheimer's trial

Despite violations at 15 out of 39 sites involved in the study, BioVie reported positive data from its trial investigating NE3107.

Deep dive into company profiles

Get a breakdown of financial data and SWOT analyses for thousands of companies, key players, and disruptors across your sector.

Search a Company
Still looking?

Search companies, themes, reports, as well as actionable data & insights spanning 22 global industries


Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward